Literature DB >> 23864630

Targeting of human antigen-presenting cell subsets.

Cleo Goyvaerts1, Jozef Dingemans, Kurt De Groeve, Carlo Heirman, Ellen Van Gulck, Guido Vanham, Patrick De Baetselier, Kris Thielemans, Geert Raes, Karine Breckpot.   

Abstract

Antigen-presenting cells are a heterogeneous group of cells that are characterized by their functional specialization. Consequently, targeting specific antigen-presenting cell subsets offers opportunities to induce distinct T cell responses. Here we report on the generation and use of nanobodies (Nbs) to target lentivectors specifically to human lymph node-resident myeloid dendritic cells, demonstrating that Nbs represent a powerful tool to redirect lentivectors to human antigen-presenting cell subsets.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23864630      PMCID: PMC3807283          DOI: 10.1128/JVI.01498-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  14 in total

Review 1.  Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity.

Authors:  Y J Liu
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  Nanobodies as tools for in vivo imaging of specific immune cell types.

Authors:  Kurt De Groeve; Nick Deschacht; Celine De Koninck; Vicky Caveliers; Tony Lahoutte; Nick Devoogdt; Serge Muyldermans; Patrick De Baetselier; Geert Raes
Journal:  J Nucl Med       Date:  2010-04-15       Impact factor: 10.057

Review 3.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

Review 4.  Dendritic cell subsets in health and disease.

Authors:  Hideki Ueno; Eynav Klechevsky; Rimpei Morita; Caroline Aspord; Tinghua Cao; Toshimichi Matsui; Tiziana Di Pucchio; John Connolly; Joseph W Fay; Virginia Pascual; A Karolina Palucka; Jacques Banchereau
Journal:  Immunol Rev       Date:  2007-10       Impact factor: 12.988

Review 5.  DC subsets in positive and negative regulation of immunity.

Authors:  Caroline Coquerelle; Muriel Moser
Journal:  Immunol Rev       Date:  2010-03       Impact factor: 12.988

6.  Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins.

Authors:  Kouki Morizono; Amy Ku; Yiming Xie; Airi Harui; Sam K P Kung; Michael D Roth; Benhur Lee; Irvin S Y Chen
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

7.  HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.

Authors:  Karine Breckpot; David Escors; Frederick Arce; Lucienne Lopes; Katarzyna Karwacz; Sandra Van Lint; Marleen Keyaerts; Mary Collins
Journal:  J Virol       Date:  2010-03-17       Impact factor: 5.103

8.  Engineered lentivector targeting of dendritic cells for in vivo immunization.

Authors:  Lili Yang; Haiguang Yang; Kendra Rideout; Taehoon Cho; Kye Il Joo; Leslie Ziegler; Abigail Elliot; Anthony Walls; Dongzi Yu; David Baltimore; Pin Wang
Journal:  Nat Biotechnol       Date:  2008-02-24       Impact factor: 54.908

9.  Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells.

Authors:  C Goyvaerts; K De Groeve; J Dingemans; S Van Lint; L Robays; C Heirman; J Reiser; X-Y Zhang; K Thielemans; P De Baetselier; G Raes; K Breckpot
Journal:  Gene Ther       Date:  2012-01-12       Impact factor: 5.250

10.  Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution.

Authors:  R M Steinman; Z A Cohn
Journal:  J Exp Med       Date:  1973-05-01       Impact factor: 14.307

View more
  19 in total

1.  Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery.

Authors:  C Goyvaerts; Y De Vlaeminck; D Escors; S Lienenklaus; M Keyaerts; G Raes; K Breckpot
Journal:  Gene Ther       Date:  2017-05-25       Impact factor: 5.250

2.  Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature.

Authors:  Roshank Ahani; Farzin Roohvand; Reza Ahangari Cohan; Mohammad Hossein Etemadzadeh; Nasir Mohajel; Mahdi Behdani; Zahra Shahosseini; Navid Madani; Kayhan Azadmanesh
Journal:  Mol Biotechnol       Date:  2016-11       Impact factor: 2.695

3.  CD80 and CD86 knockdown in dendritic cells regulates Th1/Th2 cytokine production in asthmatic mice.

Authors:  Jian-Guo Li; Yu-Mo DU; Zhi-Dong Yan; Jia Yan; Yong-Xun Zhuansun; Rui Chen; Wei Zhang; Su-Ling Feng; Pi-Xin Ran
Journal:  Exp Ther Med       Date:  2016-01-13       Impact factor: 2.447

Review 4.  Reconstructing the immune system with lentiviral vectors.

Authors:  Henning Olbrich; Constanze Slabik; Renata Stripecke
Journal:  Virus Genes       Date:  2017-07-25       Impact factor: 2.332

5.  Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.

Authors:  Katrijn Broos; Marleen Keyaerts; Quentin Lecocq; Dries Renmans; Tham Nguyen; David Escors; Adrian Liston; Geert Raes; Karine Breckpot; Nick Devoogdt
Journal:  Oncotarget       Date:  2017-06-27

Review 6.  Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.

Authors:  Cleo Goyvaerts; Karine Breckpot
Journal:  J Immunol Res       Date:  2015-10-25       Impact factor: 4.818

7.  Immunogenicity of targeted lentivectors.

Authors:  Cleo Goyvaerts; De Groeve Kurt; Sandra Van Lint; Carlo Heirman; Jo A Van Ginderachter; Patrick De Baetselier; Geert Raes; Kris Thielemans; Karine Breckpot
Journal:  Oncotarget       Date:  2014-02-15

Review 8.  Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy.

Authors:  Inès Dufait; Els Van Valckenborgh; Eline Menu; David Escors; Mark De Ridder; Karine Breckpot
Journal:  Oncotarget       Date:  2016-07-05

9.  First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.

Authors:  Seth M Pollack; Hailing Lu; Sacha Gnjatic; Neeta Somaiah; Ryan B O'Malley; Robin L Jones; Frank J Hsu; Jan Ter Meulen
Journal:  J Immunother       Date:  2017-10       Impact factor: 4.456

Review 10.  Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.

Authors:  Yaozhong Hu; Changxiao Liu; Serge Muyldermans
Journal:  Front Immunol       Date:  2017-11-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.